Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Quintarelli C, Sivori S, Caruso S, Carlomagno S, Falco M, Boffa I, Orlando D, Guercio M, Abbaszadeh Z, Sinibaldi M, Di Cecca S, Camera A, Cembrola B, Pitisci A, Andreani M, Vinti L, Gattari S, Del Bufalo F, Algeri M, Li Pira G, Moseley A, De Angelis B, Moretta L, Locatelli F.

Leukemia. 2019 Nov 19. doi: 10.1038/s41375-019-0613-7. [Epub ahead of print]

PMID:
31745215
2.

NK Cell-Based Immunotherapy for Hematological Malignancies.

Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M, Moretta L, Locatelli F, Pende D.

J Clin Med. 2019 Oct 16;8(10). pii: E1702. doi: 10.3390/jcm8101702. Review.

3.

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.

Ingegnere T, Mariotti FR, Pelosi A, Quintarelli C, De Angelis B, Tumino N, Besi F, Cantoni C, Locatelli F, Vacca P, Moretta L.

Front Immunol. 2019 Apr 30;10:957. doi: 10.3389/fimmu.2019.00957. eCollection 2019.

4.

Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.

Pallocca M, Angeli D, Palombo F, Sperati F, Milella M, Goeman F, De Nicola F, Fanciulli M, Nisticò P, Quintarelli C, Ciliberto G.

J Transl Med. 2019 Apr 23;17(1):131. doi: 10.1186/s12967-019-1865-8.

5.

[The biological resources and molecule archives organization: turn a need into an opportunity for the Smart Specialization Strategy of the Lazio region.]

Bravo E, Franchin T, Santoro F, Conti L, Carrara S, Marino M, Di Caro A, Cigliana G, Mandoj C, Baselice S, Daniele N, Giampaoli S, Quintarelli C, Salerno M, Zinno F, Russo G, Errico MC, Minghetti L, Ricciardi W, Napolitano M.

Recenti Prog Med. 2019 Feb;110(2):68-74. doi: 10.1701/3112.31001. Italian.

PMID:
30843531
6.

Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation.

Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Bufalo FD, Buatois V, Montanari P, Cefalo MG, Pitisci A, Algeri M, Galaverna F, Quintarelli C, Cirillo V, Pagliara D, Ferlin W, Ballabio M, De Min C, Locatelli F.

Haematologica. 2019 Nov;104(11):2314-2323. doi: 10.3324/haematol.2019.216101. Epub 2019 Feb 21.

7.

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.

Palermo B, Franzese O, Donna CD, Panetta M, Quintarelli C, Sperduti I, Gualtieri N, Foddai ML, Proietti E, Ferraresi V, Ciliberto G, Nisticò P.

Oncoimmunology. 2018 Sep 11;7(12):e1465163. doi: 10.1080/2162402X.2018.1465163. eCollection 2018.

8.

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I.

Oncoimmunology. 2018 Mar 15;7(6):e1433518. doi: 10.1080/2162402X.2018.1433518. eCollection 2018.

9.

Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.

Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C.

Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3.

10.

Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I.

Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017.

11.

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

Rigo V, Emionite L, Daga A, Astigiano S, Corrias MV, Quintarelli C, Locatelli F, Ferrini S, Croce M.

Sci Rep. 2017 Oct 25;7(1):14049. doi: 10.1038/s41598-017-14417-6.

12.

MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential.

Galardi A, Colletti M, Businaro P, Quintarelli C, Locatelli F, Di Giannatale A.

Curr Med Chem. 2018 Feb 13;25(5):584-600. doi: 10.2174/0929867324666171003120335. Review.

PMID:
28971761
13.

Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.

Li Pira G, Di Cecca S, Biagini S, Girolami E, Cicchetti E, Bertaina V, Quintarelli C, Caruana I, Lucarelli B, Merli P, Pagliara D, Brescia LP, Bertaina A, Montanari M, Locatelli F.

Front Immunol. 2017 Mar 23;8:332. doi: 10.3389/fimmu.2017.00332. eCollection 2017.

14.

Overcoming Challenges in CAR T-cell Product CGMP Release.

Quintarelli C, Locatelli F, Caruana I, De Angelis B.

Mol Ther. 2016 May;24(5):845-6. doi: 10.1038/mt.2016.72. No abstract available.

15.

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.

Montano G, Vidovic K, Palladino C, Cesaro E, Sodaro G, Quintarelli C, De Angelis B, Errichiello S, Pane F, Izzo P, Grosso M, Gullberg U, Costanzo P.

Oncotarget. 2015 Sep 29;6(29):28223-37. doi: 10.18632/oncotarget.4950.

16.

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P.

Leuk Lymphoma. 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. Epub 2015 Jan 23.

PMID:
25363400
17.

Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.

Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G, Pettinato G, Salvatore C, Quintarelli C, Pane F.

Radiology. 2014 Jul;272(1):262-74. doi: 10.1148/radiol.14132154. Epub 2014 Apr 6.

PMID:
24708193
18.

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F.

Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15.

PMID:
24280282
19.

Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.

Colavita I, Esposito N, Quintarelli C, Nigro E, Pane F, Ruoppolo M, Salvatore F.

Proteomics. 2013 Aug;13(16):2414-8. doi: 10.1002/pmic.201200444. Epub 2013 Jul 16.

20.

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.

Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F.

Blood. 2011 Sep 29;118(13):3634-44. doi: 10.1182/blood-2011-03-341073. Epub 2011 Aug 5.

PMID:
21821701
21.

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.

Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B.

Blood. 2011 Mar 24;117(12):3353-62. doi: 10.1182/blood-2010-08-300376. Epub 2011 Jan 28.

22.

Gene therapy to improve function of T cells for adoptive immunotherapy.

Quintarelli C, Savoldo B, Dotti G.

Methods Mol Biol. 2010;651:119-30. doi: 10.1007/978-1-60761-786-0_8.

PMID:
20686964
23.

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Leukemia. 2010 Jun;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub 2010 Apr 29.

24.

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).

De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B.

Blood. 2009 Nov 26;114(23):4784-91. doi: 10.1182/blood-2009-07-230482. Epub 2009 Sep 16.

25.

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Mol Ther. 2009 May;17(5):880-8. doi: 10.1038/mt.2009.34. Epub 2009 Mar 3.

26.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B.

Blood. 2008 Sep 1;112(5):1876-85. doi: 10.1182/blood-2008-04-150045. Epub 2008 Jun 30.

27.

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Blood. 2007 Oct 15;110(8):2793-802. Epub 2007 Jul 17.

28.

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R; GIMEMA group.

Leukemia. 2005 Apr;19(4):628-35.

PMID:
15744351
29.

Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.

Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.

Haematologica. 2003 Nov;88(11):1296-303.

30.

BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations.

Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F.

Oncogene. 2002 Dec 9;21(56):8652-67. Review.

31.

A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia.

Pane F, Intrieri M, Izzo B, Quintarelli C, Vitale D, Migliorati R, Sebastio L, Salvatore F.

Blood. 2002 Dec 1;100(12):4247-8. No abstract available.

PMID:
12433702
32.

Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.

Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Valesini G, Violi F.

Circulation. 1997 Mar 18;95(6):1425-32.

PMID:
9118509
33.

Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole.

Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F.

Br J Pharmacol. 1996 Dec;119(7):1438-46.

34.

Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group.

Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C.

Thromb Haemost. 1996 Aug;76(2):177-83.

PMID:
8865526
35.

High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.

Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F.

Hepatology. 1996 Jun;23(6):1377-83.

PMID:
8675154
36.

Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis.

Violi F, Ferro D, Basili S, Saliola M, Quintarelli C, Alessandri C, Cordova C.

Gastroenterology. 1995 Aug;109(2):531-9.

PMID:
7615203
37.

Antiphospholipid antibodies, hypercoagulability and thrombosis.

Violi F, Ferro D, Quintarelli C.

Haematologica. 1995 Mar-Apr;80(2 Suppl):131-5. Review. No abstract available.

PMID:
7628766
38.

Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels.

Quintarelli C, Ferro D, Valesini G, Basili S, Tassone G, Violi F.

J Hepatol. 1994 Dec;21(6):1086-91.

PMID:
7699232
39.

Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver.

Violi F, Ferro D, Basili S, D'Angelo A, Mazzola G, Quintarelli C, Cordova C.

BMJ. 1994 Jul 23;309(6949):239-40. No abstract available.

40.

Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus.

Ferro D, Quintarelli C, Valesini G, Violi F.

Blood. 1994 Jan 1;83(1):304. No abstract available.

PMID:
8274747
41.

Lupus anticoagulant and the fibrinolytic system in young patients with stroke.

Ferro D, Quintarelli C, Rasura M, Antonini G, Violi F.

Stroke. 1993 Mar;24(3):368-70.

PMID:
8446971
42.

Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis.

Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F.

Hepatology. 1993 Jan;17(1):78-83.

PMID:
8423044
43.

1-year survey of patients with advanced liver cirrhosis. Prognostic value of clinical and laboratory indexes identified by the Cox regression model.

Ferro D, Saliola M, Quintarelli C, Alessandri C, Basili S, Cordova C, Bonavita MS, Violi F.

Scand J Gastroenterol. 1992 Oct;27(10):852-6.

PMID:
1439538
44.

Fibrinolytic balance and lupus anticoagulant in patients with repeated spontaneous fetal loss.

Ferro D, Violi F, Quintarelli C, Sebastianelli A, D'Amelio R, Zichella L, Balsano F.

BMJ. 1992 Aug 29;305(6852):504-5. No abstract available.

45.

Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Ferro D, Saliola M, Quintarelli C, Valesini G, Basili S, Grandilli AM, Bonavita MS, Violi F.

J Clin Pathol. 1992 Apr;45(4):332-8.

46.

Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis.

Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, Cordova C, Balsano F.

Hepatology. 1992 Apr;15(4):672-6.

PMID:
1551645
47.

Clotting abnormalities in chronic liver disease.

Violi F, Ferro D, Quintarelli C, Saliola M, Cordova C, Balsano F.

Dig Dis. 1992;10(3):162-72. Review.

PMID:
1611712
48.

Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.

Violi F, Ferro D, Saliola M, Quintarelli C, Basili S, Balsano F.

Eur J Clin Pharmacol. 1992;42(4):379-83.

PMID:
1516602
49.

Specificity and sensitivity of diluted aPTT and anticardiolipin antibodies towards thrombosis and miscarriages in patients with systemic lupus erythematosus.

Ferro D, Saliola M, Quintarelli C, Carlucci M, Valesini G, Violi F.

Thromb Res. 1990 Aug 1;59(3):609-17.

PMID:
2122546
50.

Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.

Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F.

BMJ. 1990 Apr 28;300(6732):1099-102.

Supplemental Content

Loading ...
Support Center